ReNeuron Group (RENE) RNS Announcements

Add to Alert list
Date Time Source Announcement
18 Nov 2021 07:00 AM
RNS
Notice of Results
01 Nov 2021 07:00 AM
RNS
Total Voting Rights
26 Oct 2021 03:09 PM
RNS
Director exit arrangements
26 Oct 2021 07:00 AM
RNS
Collaboration agreement with UCL
21 Oct 2021 07:00 AM
RNS
Director Share Purchase
20 Oct 2021 07:00 AM
RNS
Director/PDMR Interest in Share Options
18 Oct 2021 07:00 AM
RNS
Further changes in the Board of Directors
18 Oct 2021 07:00 AM
RNS
First subject treated at Oxford Eye Hospital
12 Oct 2021 02:05 PM
RNS
Second Price Monitoring Extn
12 Oct 2021 02:01 PM
RNS
Price Monitoring Extension
11 Oct 2021 04:40 PM
RNS
Second Price Monitoring Extn
11 Oct 2021 04:35 PM
RNS
Price Monitoring Extension
11 Oct 2021 02:06 PM
RNS
Second Price Monitoring Extn
11 Oct 2021 02:00 PM
RNS
Price Monitoring Extension
11 Oct 2021 11:05 AM
RNS
Second Price Monitoring Extn
11 Oct 2021 11:00 AM
RNS
Price Monitoring Extension
11 Oct 2021 09:05 AM
RNS
Second Price Monitoring Extn
11 Oct 2021 09:00 AM
RNS
Price Monitoring Extension
11 Oct 2021 07:00 AM
RNS
Positive data generated in exosome collaboration
01 Oct 2021 07:00 AM
RNS
Regulatory approval for continuation of RP trial
16 Sep 2021 04:26 PM
RNS
Result of AGM
02 Sep 2021 12:00 PM
RNS
Block Listing Review, Application and TVR
16 Aug 2021 02:20 PM
RNS
Posting of AR and Accounts and Notice of AGM
06 Aug 2021 07:00 AM
RNS
Directorate Change
14 Jul 2021 07:00 AM
RNS
Board Change
08 Jul 2021 07:00 AM
RNS
Preliminary Results for the year ended 31 March 21
02 Jul 2021 01:00 PM
RNS
Notice of Results
02 Jul 2021 07:00 AM
RNS
Notice of Results
01 Jul 2021 07:00 AM
RNS
Directorate Change
01 Jul 2021 07:00 AM
RNS
Total Voting Rights
18 Jun 2021 10:48 AM
RNS
Holding(s) in Company
09 Jun 2021 04:36 PM
RNS
Price Monitoring Extension
09 Jun 2021 02:05 PM
RNS
Second Price Monitoring Extn
09 Jun 2021 02:00 PM
RNS
Price Monitoring Extension
09 Jun 2021 11:55 AM
RNS
Update for hRPC therapy candidate study
07 Jun 2021 05:25 PM
RNS
Holding(s) in Company
20 May 2021 07:00 AM
RNS
Appointment of Chief Scientific Officer
04 May 2021 07:00 AM
RNS
Total Voting Rights
29 Apr 2021 07:00 AM
RNS
Initiation of research by Allenby Capital
06 Apr 2021 07:00 AM
RNS
Virtual conference attendance and presentations
30 Mar 2021 07:00 AM
RNS
Holding(s) in Company
19 Mar 2021 07:00 AM
RNS
Exosome platform update
16 Mar 2021 04:05 PM
RNS
Holding(s) in Company
16 Mar 2021 10:57 AM
RNS
Holding(s) in Company
16 Mar 2021 07:00 AM
RNS
Holding(s) in Company
12 Mar 2021 07:00 AM
RNS
Directorate Change
01 Mar 2021 07:00 AM
RNS
Block Listing Review and Total Voting Rights
25 Feb 2021 07:01 AM
RNS
Investor presentations
25 Feb 2021 07:00 AM
RNS
Appointment of Joint Broker
11 Feb 2021 07:00 AM
RNS
Director/PDMR Interest in Shares and Share Options

ReNeuron Group plc is a United Kingdom-based clinical-stage stem cell company. The Company is engaged in the development of stem cell therapies targeting areas of unmet or poorly met medical need. It has developed a stem cell-derived, exosome-based, drug delivery platform with customizable cellular targeting capabilities for the delivery of complex drug modalities. Through the generation of several exosome producer cell lines, its CustomEX platform can be optimized for specific tissue targets and payloads, leading to improvements in therapeutic outcome and a reduction in off-target effects. It offers a delivery mechanism for a variety of payloads such as small interfering Ribonucleic Acid (siRNA), messenger RNA (mRNA), proteins, small molecules and genes. Through its conditionally immortalized induced pluripotent stem cell (iPSC) platform, it has the ability to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

It listed on AIM in 2006 under the ticker RENE.

UK 100

Latest directors dealings